IDA-BUCY2强化预处理异基因造血干细胞移植治疗难治复发性急性髓系白血病的疗效分析

来源 :中华医学会血液学分会第九次全国造血干细胞移植学术会议 | 被引量 : 0次 | 上传用户：rzq1988

【摘要】

：

【作者】

：

夏凌辉张然王华芳游泳仲照东吴秋玲方峻洪梅石威陆铉胡豫

【机构】

：

华中科技大学同济医学院附属协和医院血液病研究所 430022

【出处】

：

中华医学会血液学分会第九次全国造血干细胞移植学术会议

【发表日期】

：

2015年4期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

目的探讨IDA-BUCY2强化预处理异基因造血干细胞移植(allo-HSCT)治疗难治复发性急性髓系白血病(AML)的有效性及安全性.方法对2004年10月至2015年3月于我院行allo-HSCT的66例难治复发性AML患者进行回顾性分析,44例采用IDA-BUCY2强化预处理方案,22例采用改良BUCY2方案,比较两组移植后急慢性移植物抗宿主病(GVHD)、复发率、移植相关死亡率(TRM)、总体生存率(OS)及无病生存率(DFS)的差异.结果除IDA-BUCY2强化预处理组1例患者于移植后22天因肺部真菌感染死亡外,余患者均获得造血重建,两组中性粒细胞及血小板恢复时间无明显差异.

其他文献

Future of HSCT in Aging Country-Japanese Perspective

Proportion of elderly population (age 65 ≤)is rapidly growing in Japan Characteristics of aged HSCs Low repopulation potential Less homing Myeloid lineage bias Higher risk of malignant transformation

会议

Post-transplantcyclophosphamide for GvHD prophylaxis in matched sibling donor allogeneic hematopoiet

Currently, standard GvHD prophylaxis in matched sibling donor allogeneic hematopoietic stem cell transplant is the combination of short course methotrexate and calcineurin inhibitor including cyclospo

会议

The identification and pathological roles of IL-22 in acute graft-versus-host disease following allo

Immunopathogenesis of GVHD Central role of CD4+ T cells in GVHD Recent studies on Th22/IL-22 in GVHD Administration of IL-22 enhanced thymus recovery in mouse after total body irradiation.(Science 201

会议

Hematopoietic Stem Cell Transplantation and Bone Marrow Microenvironment

Leukemia remains a serious disease with high morbidity and mortality Elizabeth W,et al.CA Cancer J Clin.2014 Cornelissen JJ,et al.Blood,2007allo-HSCT is an effective treatment for leukemia Allo-HSCT t

会议

Uniform Conditioning Regimen and Identical GVHD Prophylaxis for Haploidentical, Unmanipulated, G-CSF

Background During the last years, hematopoietic stem cell transplant from haploidentical donor is increasing by using the unmanipulated graft.We report an update of the results of allogeneic bone marr

会议

Hematopoietic Stem Cell Transplantation in treatment of Philadelphia Chromosome-Positive Acute Lymph

Background Ph+ ALL is a high-risk subset of ALL that has an extremely poor prognosis Since the introduction of TKI to combination chemotherapy regimens, the majority of newly diagnosed Ph+ ALL patient

会议

Recruitment of CD8+ T Cells into Bone Marrow Might Explain the Suppression of Megakaryocyte Apoptosi

Background PT =PLT≤80 × 109/L,w/recovery of other cell count w/o apparent cause of thrombocytopenia Kim DH,et al.J Korean Med Sci,2006,21(1);46-51Kim DH et al.Bone Marrow Transplant,2006,37(1): 101-10

会议

valproic acid ameliorate graft-versus-host disease by down-regulates TH1 and Th17 cells but preserve

目的 GVHD iis the major complication after allogeneic BMT.VPA has been described as a HDAC inhibitor which had anti-inflammatory effects and could reduce the production of pro-inflammatory cytokines in

会议

儿童急性髓系白血病/骨髓增生异常综合征移植后监测WT1基因表达水平与预后关系

目的探讨监测WT1基因对急性髓系白血病(AML)及骨髓增生异常综合征(MDS)患儿进行异基因造血干细胞移植(allo-HSCT)后的临床意义.方法本文回顾性分析了2009年1月至2012年12月在我单位行allo-HSCT、且移植后连续监测WT1基因至少1年的36例儿童AML/MDS患者.留取移植后+30、+60、+90、+180、+270、+360天、+18月、+24月、+30月、+36月骨

会议

Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adu

目的 In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronic myeloid leukemia (CML) in chronic or accelerated phase.Although second-generation TKIs (TKI2

会议

IDA-BUCY2强化预处理异基因造血干细胞移植治疗难治复发性急性髓系白血病的疗效分析

其他学术论文